Corticosteroids and superinfections in COVID-19 patients on invasive mechanical ventilation
dc.contributor.author | Søvik, Signe | |
dc.contributor.author | Barrat-Due, Andreas | |
dc.contributor.author | Kåsine, Trine | |
dc.contributor.author | Olasveengen, Theresa M. | |
dc.contributor.author | Strand, Marianne Wigernes | |
dc.contributor.author | Tveita, Anders Aune | |
dc.contributor.author | Berdal, Jan-Erik | |
dc.contributor.author | Lehre, Martin Andreas | |
dc.contributor.author | Lorentsen, Torleif | |
dc.contributor.author | Heggelund, Lars | |
dc.contributor.author | Stenstad, Tore | |
dc.contributor.author | Ringstad, Jetmund | |
dc.contributor.author | Müller, Fredrik | |
dc.contributor.author | Aukrust, Pål | |
dc.contributor.author | Holter, Jan Cato | |
dc.contributor.author | Nordøy, Ingvild | |
dc.date.accessioned | 2022-09-16T07:28:59Z | |
dc.date.available | 2022-09-16T07:28:59Z | |
dc.date.created | 2022-06-01T14:12:03Z | |
dc.date.issued | 2022 | |
dc.identifier.issn | 0163-4453 | |
dc.identifier.uri | https://hdl.handle.net/11250/3018287 | |
dc.description.abstract | Objectives To determine the incidence and characteristics of superinfections in mechanically ventilated COVID-19 patients, and the impact of dexamethasone as standard therapy. Methods This multicentre, observational, retrospective study included patients ≥ 18 years admitted from March 1st 2020 to January 31st 2021 with COVID-19 infection who received mechanical ventilation. Patient characteristics, clinical characteristics, therapy and survival were examined. Results 155/156 patients (115 men, mean age 62 years, range 26-84 years) were included. 67 patients (43%) had 90 superinfections, pneumonia dominated (78%). Superinfections were associated with receiving dexamethasone (66% vs 32%, p<0.0001), autoimmune disease (18% vs 5.7%, p<0.016) and with longer ICU stays (26 vs 17 days, p<0,001). Invasive fungal infections were reported exclusively in dexamethasone-treated patients [8/67 (12%) vs 0/88 (0%), p<0.0001]. Unadjusted 90-day survival did not differ between patients with or without superinfections (64% vs 73%, p=0.25), but was lower in patients receiving dexamethasone versus not (58% vs 78%, p=0.007). In multiple regression analysis, superinfection was associated with dexamethasone use [OR 3.7 (1.80–7.61), p<0.001], pre-existing autoimmune disease [OR 3.82 (1.13–12.9), p=0.031] and length of ICU stay [OR 1.05 p<0.001]. Conclusions In critically ill COVID-19 patients, dexamethasone as standard of care was strongly and independently associated with superinfections. | en_US |
dc.language.iso | eng | en_US |
dc.publisher | Elsevier | en_US |
dc.relation.uri | https://www.sciencedirect.com/science/article/pii/S016344532200305X?via%3Dihub | |
dc.rights | Navngivelse 4.0 Internasjonal | * |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/deed.no | * |
dc.title | Corticosteroids and superinfections in COVID-19 patients on invasive mechanical ventilation | en_US |
dc.type | Journal article | en_US |
dc.type | Peer reviewed | en_US |
dc.description.version | publishedVersion | en_US |
dc.rights.holder | Copyright 2022 The Author(s) | en_US |
cristin.ispublished | true | |
cristin.fulltext | original | |
cristin.qualitycode | 2 | |
dc.identifier.doi | 10.1016/j.jinf.2022.05.015 | |
dc.identifier.cristin | 2028774 | |
dc.source.journal | Journal of Infection | en_US |
dc.source.pagenumber | 57-63 | en_US |
dc.identifier.citation | Journal of Infection. 2022, 85 (1), 57-63. | en_US |
dc.source.volume | 85 | en_US |
dc.source.issue | 1 | en_US |
Tilhørende fil(er)
Denne innførselen finnes i følgende samling(er)
-
Department of Clinical Science [2291]
-
Registrations from Cristin [9482]